GlassScriptPhysician profile
Nezar Dahdal
NPI 1194977405
$3,214.92
in general payments reported to CMS, 2019-2025
21 companies · $741 in 2025
The $741 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.34 · 2022: $819 · 2023: $849 · 2024: $730 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.83 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $437.04 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $389.73 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $338.00 | 2021-2024 | Lifevest |
| Abbvie INC. | $275.90 | 2022-2024 | Linzess, Creon, Viberzi |
| Amgen INC. | $225.07 | 2022-2025 | Otezla, Repatha, Otezla |
| Edwards Lifesciences Corporation | $180.58 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Nestle Healthcare Nutrition INC. | $144.17 | 2022-2023 | |
| Abbott Laboratories | $143.63 | 2022-2025 | Octrode, Cardiomems, Mitraclip |
| Aimmune Therapeutics, INC. | $138.72 | 2025 | Zenpep |
| Pfizer INC. | $102.35 | 2024-2025 | |
| Glaxosmithkline, LLC. | $85.00 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $65.56 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $36.81 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.95 | 2023 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $31.84 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.19 | 2025 | Rexulti |
| Lucid Diagnostics INC. | $26.80 | 2021 | |
| Corcept Therapeutics | $22.89 | 2023 | Korlym |
| Medtronic, INC. | $22.22 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nezar Dahdal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.